You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
熱景生物(688068.SH):預計2024年淨虧損1.75億元-2億元
格隆匯 01-14 16:03

格隆匯1月14日丨熱景生物(688068.SH)公佈,經財務部門初步測算,預計2024年年度實現營業收入49,000萬元至52,000萬元,與上年同期(法定披露數據)相比,同比減少3.93%至9.47%。預計2024年度實現歸屬於母公司所有者的淨利潤-17,500萬元至-20,000萬元。與上年同期相比,將出現虧損。預計2024年年度歸屬於母公司所有者的扣除非經常性損益的淨利潤-24,000萬元至-26,500萬元。

1、報吿期內,公司始終堅持科創定位和高質量發展,持續保持對臨牀免疫診斷、分子診斷等技術平台的研發投入;並加大對創新產品的研發探索,常規臨牀產品的轉化及註冊力度;研發費用保持較高投入,在營業收入規模未實現大幅增長時對公司淨利潤產生了一定不利影響。2、報吿期內,隨着醫療集採的持續推進,行業存量競爭加劇,產品終端入院價格進一步下降,公司的單機收入和單機產出率呈現不同程度的下滑。上述因素,對公司的綜合毛利率和毛利產生較大影響;另一方面,公司按照一貫的計提減值政策進行測算,對與此相關的試劑和設備等經營資產計提了減值損失。3、報吿期內,公司聯營企業舜景醫藥、堯景基因、智源生物等持續加大在生物創新藥等領域的研發投入,導致公司確認對聯營企業的投資損失金額擴大,對公司淨利潤產生了一定不利影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account